Promega Corporation

U0126: A Novel Selective and Potent Inhibitor of MAP Kinase Kinase MEK

  • Share
  • Print
  • Email
  • Download PDF
  • Article
  • Comments & Ratings

Abstract

Mitogen-activated protein kinases (MAPKs) are involved in a number of cell signaling pathways. These enzymes are activated by dual phosphorylation of threonine and tyrosine residues in response to a multitude of extracellular stimuli. Activation of MAPKs are mediated by another set of enzymes referred to as MAPK kinases or MEKs. In this article, we introduce MEK Inhibitor U0126, a compound that exhibits potent MEK inhibitor activity both in vitro and in vivo.

Promega Notes 69, 6.

Said A. Goueli, Kevin Hsiao, Tingyun Lu and Dan Simpson

Promega Corporation
Publication Date: 1998

Download Article (208 KB)

Prefer a different language?

Your country is set to Korea, Republic Of. Your language is set to 한국어. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

  • Warning
  • It appears that you have Javascript disabled. Our website requires Javascript to function correctly. Please enable Javascript to experience our website.